Phyxiom
Phyxiom is an analytics platform that transforms the clinical outcomes of patients with uncontrolled asthma and COPD. Phyxiom offers a unique solution for the 12 million people who suffer from uncontrolled asthma in the US through its 100% digital business model that is device and medication independent and delivered by a proven world-class team of clinical and technology professionals. The Phyxiom technology is the result of 10 years' of clinical research at RCSI developing a family of patented algorithms and software platforms for the management of chronic respiratory disease.
Uncontrolled asthma affects over 12 million people in the US alone. This leads to substantial healthcare costs and impact on quality of life.
Phyxiom has developed a remote diagnostics platform, which is device independent, integrating smart inhalers and spirometry devices to patient data for time-based analysis. The platform acts as an intelligent decision support system for physicians delivering patient clinical data in an easily accessible form. Supports precise diagnosis and treatment of uncontrolled asthma using patient’s own data measured over time
Promoters
- Prof. Richard Costello, CMO/Academic Founder, Co-Founder
- John Byrne, CEO
Current status
- Trials in progress across several hospital groups
- Planning for US market launch in 2025
Next steps
- Seed round €1.7m, EIIS eligible
- Customer acquisition in US/Europe
